期刊
BIOMARKER RESEARCH
卷 6, 期 -, 页码 -出版社
BMC
DOI: 10.1186/s40364-018-0131-1
关键词
Pancreatic ductal adenocarcinoma; miRNA; Biomarkers; Resistance; Prognosis; Chemotherapy; Gemcitabine
资金
- National Institute of Health/National Cancer Institute [R01CA15501904, R01CA19709801]
- National Natural Science Foundation of China [81502550]
Despite tremendous research efforts focused on diagnosis and treatment, pancreatic ductal adenocarcinoma remains the third leading cause of cancer-related death in the United States, with a 5-year overall survival rate of less than 5%. Although resistance is rather complex, emerging evidence has demonstrated that epigenetic alterations (e.g. miRNA) have important roles in PDAC progression as well as resistance to therapy. Certain miRNAs have been identified as potential prognostic biomarkers in PDAC. In this review, we summarize the recent developments in miRNA research related to PDAC therapeutic resistance mechanisms and the potential of miRNAs as prognostic biomarkers for future clinical management of PDAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据